Clinical Trial Dictionary

FDA regulation that defines the criteria under which electronic records and electronic signatures are considered trustworthy, reliable, and equivalent to paper records. It requires audit trails, access controls, and validation of systems used in FDA-regulated activities.

Any untoward medical occurrence in a clinical trial participant that does not necessarily have a causal relationship with the treatment. Adverse events include any unfavorable or unintended sign, symptom, or disease temporally associated with the use of an investigational product.

A framework for data integrity in clinical trials. ALCOA stands for Attributable, Legible, Contemporaneous, Original, and Accurate. The '+' adds Complete, Consistent, Enduring, and Available. These principles ensure data quality and compliance.

A formal change to an approved clinical trial protocol that must be reviewed and authorized by the IRB/ethics committee and regulatory authorities before implementation. Amendments may modify study design, eligibility criteria, dosing, endpoints, or other critical aspects of the trial.

A secure, time-stamped, computer-generated record that tracks the creation, modification, and deletion of electronic data. Audit trails are required by 21 CFR Part 11 and ICH GCP to ensure data integrity and provide a reliable history of all actions taken on regulated records.

A legally binding contract required under HIPAA between a covered entity and a business associate that handles protected health information (PHI). The BAA establishes the permitted uses and disclosures of PHI, requires safeguards, and mandates breach notification procedures.

A regulatory standard demonstrating that two pharmaceutical products are equivalent in their rate and extent of drug absorption. Bioequivalence studies are essential for generic drug approvals and are typically measured through pharmacokinetic parameters such as AUC and Cmax.

A procedure in which one or more parties involved in a clinical trial are kept unaware of treatment assignments. Single-blind means subjects do not know their assignment; double-blind means neither subjects nor investigators know. Blinding reduces bias in the evaluation of outcomes.

A standardized document or electronic form used to collect and record clinical trial data for each study participant. CRFs are designed to capture all protocol-required information and serve as the primary source for data analysis and regulatory review.

A global standards organization that develops data standards for clinical research to streamline data collection, exchange, submission, and archival. Key standards include CDASH for data collection, SDTM for submission datasets, and ADaM for analysis datasets.

The process of collecting, cleaning, validating, and managing clinical trial data to ensure it meets regulatory quality standards. CDM encompasses database design, data entry, query resolution, medical coding, and database lock procedures.

A measurable outcome or event in a clinical trial that serves as evidence of the treatment's effect. Endpoints can be primary (the main outcome) or secondary, and may include clinical measures, biomarkers, patient-reported outcomes, or survival rates.

A defined group of participants within a clinical trial who share a common characteristic, such as receiving the same treatment or dose level. Cohort-based designs are common in dose-escalation studies and observational research.

The systematic process of obtaining, documenting, tracking, and maintaining informed consent from clinical trial participants. Effective consent management ensures regulatory compliance and provides a verifiable record that participants voluntarily agreed to study participation.

A group of participants in a clinical trial that receives a standard treatment, placebo, or no intervention for comparison against the experimental group. Control groups are essential for establishing whether the investigational treatment produces a statistically significant effect.

A company hired by a sponsor to manage clinical trial activities, from study design and site selection to data management and regulatory submissions. CROs help sponsors execute trials without building internal infrastructure.

The point at which a clinical trial database is frozen and no further changes can be made to the data. Database lock occurs after all queries have been resolved, data has been cleaned, and medical coding is complete. It is a critical milestone before statistical analysis begins.

An independent group of experts that reviews accumulating safety and efficacy data from an ongoing clinical trial at regular intervals. The DMC may recommend trial modifications, continuation, or early termination based on their assessment of benefit-risk balance.

A clinical trial conducted partially or entirely outside traditional clinical sites, leveraging telemedicine, remote monitoring, direct-to-patient drug delivery, and digital health technologies. DCTs improve participant access and reduce the burden of site visits.

A legally binding contract required under GDPR between a data controller and a data processor that governs the processing of personal data. DPAs define the scope, purpose, and duration of processing, as well as the obligations of each party regarding data protection.

A digital method of obtaining informed consent from clinical trial participants using electronic systems. eConsent platforms present study information through multimedia formats, verify comprehension, and capture legally binding electronic signatures.

Software used to collect clinical trial data electronically rather than on paper case report forms (CRFs). Modern EDC systems include features like data validation, query management, and reporting.

The ability of an investigational treatment to produce a desired therapeutic effect under controlled clinical trial conditions. Efficacy is measured against predefined endpoints and compared to control groups to determine whether the treatment provides statistically significant benefit.

A digital system for storing and managing all essential documents required at the clinical site level per ICH GCP. It replaces paper binders and provides instant access to regulatory documents, source data, and correspondence.

A predefined, measurable outcome in a clinical trial used to evaluate whether the investigational treatment has an effect. Endpoints are classified as primary, secondary, or exploratory and may include clinical outcomes, biomarkers, or patient-reported measures.

The process of recruiting and registering eligible participants into a clinical trial. Enrollment begins after informed consent is obtained and eligibility is confirmed, and is tracked as a key performance metric for trial progress and timeline management.

The capture of clinical trial data electronically at the point of care, creating the original electronic source record. eSource eliminates transcription from paper to electronic systems, improving data accuracy and enabling real-time data access for monitors and sponsors.

A digital repository of all essential documents related to a clinical trial, maintained by the sponsor. It serves as evidence that the trial was conducted in compliance with regulations and the protocol.

The United States federal agency responsible for protecting public health by regulating food, drugs, biologics, medical devices, and cosmetics. The FDA reviews and approves new drug applications, oversees clinical trial conduct, and enforces compliance with federal regulations.

A critical clinical trial milestone marking the date when the first participant is enrolled and begins study procedures. FPI is a key metric for assessing study startup efficiency and is used to track timelines against projected enrollment schedules.

An international ethical and scientific quality standard for the design, conduct, performance, monitoring, auditing, recording, analysis, and reporting of clinical trials. GCP compliance ensures that participant rights, safety, and well-being are protected and that trial data is credible.

The European Union regulation governing the collection, processing, and storage of personal data for individuals within the EU and EEA. GDPR imposes strict requirements on data controllers and processors, including lawful basis for processing, data minimization, and the right to erasure.

A standardized security assessment framework used primarily by higher education institutions to evaluate the security posture of third-party vendors and cloud service providers. HECVAT assesses areas including data protection, access controls, incident response, and compliance.

A United States federal law that establishes national standards for the protection of individually identifiable health information. HIPAA's Privacy Rule and Security Rule require administrative, physical, and technical safeguards for protected health information (PHI).

An international ethical and scientific quality standard for designing, conducting, recording, and reporting trials that involve the participation of human subjects. Compliance provides public assurance that the rights, safety, and well-being of trial subjects are protected.

The process by which a potential clinical trial participant voluntarily confirms their willingness to participate after being fully informed of all relevant aspects of the study. This includes the purpose, procedures, risks, benefits, alternatives, and their right to withdraw at any time.

An independent committee formally designated to review, approve, and monitor biomedical research involving human subjects. The IRB ensures that participant rights and welfare are protected, that risks are minimized, and that informed consent is properly obtained.

A planned statistical analysis of clinical trial data conducted before the study is completed, typically at predefined time points or after a specified number of events. Interim analyses allow for early assessment of efficacy, futility, or safety concerns.

A comprehensive document compiled by the sponsor that summarizes all clinical and non-clinical data relevant to the study of an investigational product in human subjects. The IB provides investigators with the information needed to make informed decisions about study conduct and patient management.

A clinical trial milestone marking the date when the final enrolled participant completes their last study visit or procedure. LPO signals the end of data collection and triggers the final steps of data cleaning, database lock, and study close-out.

The process of translating clinical trial terms such as adverse events, medical history, and concomitant medications into standardized dictionary codes. Common coding dictionaries include MedDRA for adverse events and WHO Drug Dictionary for medications.

The act of overseeing the progress of a clinical trial to ensure it is conducted, recorded, and reported in accordance with the protocol, SOPs, GCP, and regulatory requirements. Monitoring may be performed on-site, remotely, or through a centralized approach.

A clinical trial conducted simultaneously at multiple investigational sites, often across different geographic regions. Multi-site trials increase enrollment capacity and diversity but require robust coordination of study conduct, data collection, and regulatory submissions across all locations.

A formal submission to the FDA requesting approval to market a new pharmaceutical product in the United States. The NDA includes all preclinical and clinical trial data, manufacturing information, labeling, and proposed use to demonstrate the drug's safety and efficacy.

A pharmaceutical product developed to treat a rare disease or condition affecting a small patient population, typically fewer than 200,000 people in the United States. Orphan drug designation provides regulatory incentives including tax credits, fee waivers, and extended market exclusivity.

The process of identifying, screening, and enrolling eligible participants into a clinical trial. Effective recruitment strategies are critical to meeting enrollment targets and timelines, and may involve advertising, physician referrals, database searches, and digital outreach.

The science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or other drug-related problems. Pharmacovigilance spans the entire product lifecycle from clinical development through post-marketing surveillance.

The sequential phases of clinical drug development. Phase I evaluates safety and dosage in a small group. Phase II assesses efficacy and side effects. Phase III confirms effectiveness in large populations. Phase IV conducts post-marketing surveillance after regulatory approval.

The qualified individual responsible for the conduct of a clinical trial at a specific site. The PI oversees all study procedures, ensures participant safety, maintains regulatory compliance, and is accountable for the quality and integrity of data collected at their site.

A detailed written plan that describes the objectives, design, methodology, statistical considerations, and organization of a clinical trial. The protocol ensures consistent study conduct across all sites and serves as the foundation for regulatory review and approval.

Any departure from the approved clinical trial protocol that is not prospectively approved by the IRB. Deviations may be major (affecting participant safety or data integrity) or minor, and must be documented, reported, and assessed for their impact on the trial.

A formalized system that documents processes, procedures, and responsibilities for achieving quality objectives in clinical research. A QMS ensures that trial activities are conducted consistently and in compliance with regulatory requirements, with a focus on continuous improvement.

The process of identifying, issuing, tracking, and resolving data discrepancies found during clinical data review. Queries are raised when data appears incomplete, inconsistent, or implausible, and must be resolved by the site before the database can be locked.

The process of assigning clinical trial participants to treatment or control groups by chance to minimize bias. Randomization methods include simple, block, stratified, and adaptive approaches, each designed to ensure balanced group allocation and valid statistical comparisons.

The formal process of submitting documentation to a regulatory authority for review and approval of a clinical trial or marketing application. Submissions include INDs, NDAs, BLAs, and their international equivalents, along with all supporting clinical, nonclinical, and manufacturing data.

A monitoring approach that focuses oversight activities on the most critical data points and processes to participant safety and data integrity. RBM uses centralized data review, key risk indicators, and targeted on-site visits to optimize monitoring resources.

A technology system that manages participant randomization and the allocation and distribution of investigational products in a clinical trial. RTSM ensures the right drug supply reaches the right site at the right time while maintaining blinding integrity.

Any untoward medical occurrence that results in death, is life-threatening, requires hospitalization, causes disability, or results in a congenital anomaly. SAEs must be reported to regulatory authorities within strict timelines.

A visit conducted by the sponsor or CRO to a clinical trial site before enrollment begins. The SIV ensures that the site is properly set up, staff are trained, supplies are available, and all regulatory requirements are met for the trial to begin.

The process by which a clinical research associate compares data recorded in the CRF or EDC system against the original source documents to ensure accuracy and completeness. SDV is a core component of clinical trial monitoring.

The individual, company, institution, or organization that initiates, manages, and finances a clinical trial. The sponsor is responsible for the overall conduct of the trial, regulatory submissions, safety reporting, and ensuring compliance with GCP and applicable regulations.

The process of initiating a clinical trial, encompassing site selection, regulatory submissions, contract negotiations, IRB approvals, site training, and system setup. Study startup timelines are a critical determinant of overall trial duration and cost.

A medical specialty or disease category within which a clinical trial is conducted. Common therapeutic areas include oncology, cardiology, neurology, immunology, and infectious disease. Each area has unique regulatory considerations and endpoint requirements.

The collection of essential documents that individually and collectively permit the evaluation of the conduct of a trial and the quality of the data produced. The TMF is maintained throughout the trial lifecycle and must be available for regulatory inspection at any time.

The process of revealing treatment assignments in a blinded clinical trial. Unblinding may occur at the planned end of the study for data analysis, or in emergency situations when knowledge of treatment assignment is necessary for participant safety and medical management.

The documented process of demonstrating that a computerized system, process, or method consistently produces results meeting predetermined specifications and quality attributes. In clinical trials, validation applies to EDC systems, laboratory equipment, and analytical methods.